Intravenous Plasma Treatment for Parkinson's Disease (yFFP)
Intravenous Young Fresh Frozen Plasma (yFFP) Investigational Treatment for Parkinson's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The Neurology Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of Parkinson's disease
- Disease duration of 1 to 5 years
- Willingness to confirm the use of adequate birth control while on the trial will be required in premenopausal women without evidence for an inability to become pregnant.
- Willingness to not start any other treatment for Parkinson's or Multiple Sclerosis during the parallel part of the trial.
Exclusion Criteria:
- Other significant disease, which in the view of the study doctor may make assessment of the efficacy of yFFP difficult.
- Unstable medical conditions.
- Must weigh at least 45.5 kg. Cannot weigh more than 130 kg.
- A severe disease state diagnosis
- Litigation. Patients in litigation will be excluded only if conclusion of that litigation is imminent during the course of the study.
- If patient is pregnant or breastfeeding.
- Complete IgA deficiency.
- Rare contraindications to yFFP therapy as per summary of product characteristics.
- Receiving yFFP for other reasons.
- Ongoing drug or alcohol abuse.
- Psychiatric disorder that could, in the judgement of the site investigator, interfere with successful study participation.
- Unwillingness or inability to complete the study or an inability to understand the questionnaires being used.
- Cancer other than basal cell carcinoma within the last 5 years. However, those patients who have received definitive treatment, such as curative surgery more than 6 months ago, with no known recurrence can be included.
- A history of hypercoagulable or thrombophilic clotting abnormalities.
- A history of thromboembolic events: ischaemic stroke, confirmed myocardial infarction, pulmonary embolism; deep venous thrombosis except where immobility related (for example, after injury or operation).
- Unstable angina pectoris.
- Medications that might react with yFFP such as blood thinners
- Renal failure or serum creatinine greater than 1.5 times the upper limit of normal at screening.
- Any medical condition that, in the opinion of the investigator, would make it unsafe for the patient to participate or which would interfere with assessment of the outcome measures.
- Participation in another interventional trial within 3 months of randomization. Participation in non-interventional studies is not a reason for exclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Young Fresh Frozen Plasma (yFFP)
[21CFR640.30]
Plasma from 18 - 25 year old volunteer donors
|
12.5 ml/kg intravenous Spectrum Plasma yFFP, per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Other Names:
|
|
Placebo Comparator: Saline
0.1% riboflavin in normal saline
|
12.5 ml/kg intravenous 0.9% sodium chloride with 0.1% riboflavin , per each of two infusions (25 ml/kg total), in combination with ongoing normal standard treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Physician assessment
Time Frame: Two weeks prior to infusion, at one-three-six months post-infusion
|
Unified Parkinson Disease Rating Scale (UPDRS)
|
Two weeks prior to infusion, at one-three-six months post-infusion
|
|
Patient assessment
Time Frame: Two weeks prior to infusion, at one-three-six months post-infusion
|
Changes in Stanford Presenteeism Scale (SPS)
|
Two weeks prior to infusion, at one-three-six months post-infusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stability of administration
Time Frame: At the time of infusions, day 1 and day 2
|
Adverse events (if any)
|
At the time of infusions, day 1 and day 2
|
|
Factors predicting a beneficial response
Time Frame: After the last participant's final contact at 6 months
|
Patient Global Impression of change
|
After the last participant's final contact at 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dian Ginsberg, M.D., The Ginstitute of Functional Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NeurologyCenter
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.